Conversations on Mental Health: Sharmin Ghaznavi, MD, PhD, & The Center for the Neuroscience of Psychedelics
Mass General researchers are testing the psychedelic compound psilocybin as a therapeutic for treatment-resistant depression.
Treats:
Medical Education
American Board Certifications
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
Secure online access to your health information whenever you need it. Check appointments, communicate with your provider and pay bills online 24/7.
The Center for Neuroscience of Psychedelics has been brought to life by generous donations from our partners.
Mass General is the #1 hospital in New England based on U.S. News & World Report Best Hospitals for 2022-2023.
Mass General researchers are testing the psychedelic compound psilocybin as a therapeutic for treatment-resistant depression.
The center’s mission is to understand how psychedelics enhance the brain’s capacity for change, to optimize current treatments and create new treatments for mental illness and to render the term “treatment resistant” obsolete.